Scarica l'app Stockscreener
7.00
0.21%
0.015
Precedente Chiudi:
$6.985
Aprire:
$6.98
Volume 24 ore:
460.94K
Relative Volume:
0.34
Capitalizzazione di mercato:
$565.90M
Reddito:
$204.89M
Utile/perdita netta:
$-157.30M
Rapporto P/E:
-3.3158
EPS:
-2.1111
Flusso di cassa netto:
$-97.76M
1 W Prestazione:
-9.68%
1M Prestazione:
-19.17%
6M Prestazione:
-30.42%
1 anno Prestazione:
-40.22%
Intervallo 1D:
$6.91
$7.19
Intervallo di 1 settimana:
$6.91
$7.84
Portata 52W:
$6.91
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
6.995 | 565.09M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
522.75 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.33 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
186.22 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.26 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
194.65 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-12-12 | Iniziato | Raymond James | Strong Buy |
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Technical Reactions to PHAT Trends in Macro Strategies - Stock Traders Daily
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law - The National Law Review
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals targets gastroenterolog... - Pluang
PHAT Initiates Coverage On Leerink Partners -- Rating Set to Mar - GuruFocus
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha
Phathom at Cantor conference: growth, access and new uses - Investing.com
PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10 - Moomoo
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT - marketscreener.com
Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us
Phathom Pharmaceuticals Inc. (PHAT) Peer Comparison – Compare with Others - Value Research
PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - ad-hoc-news.de
PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - ad-hoc-news.de
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - finance.yahoo.com
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc. - MarketBeat
Phathom Pharmaceuticals Inc. (PHAT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom (PHAT) Levels: Ends Up by 0.39% at $8.90 for the Current Session; Chart View: the Supplied Trading Band Runs From $8.46 to $9.35 on the DayAggressive Growth Picks - siam.in
Phathom (PHAT) Today: Moves 3.14% Higher to $8.87 in the Latest Session; Current Setup - dars.gov.et
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN) - theglobeandmail.com
PHAT Maintains Overweight Rating -- Price Target Lowered to $14 - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Phathom Pharmaceuticals (PHAT) Advances 4.36% to $9.58, Approaches Key Resistance at $10.06MESA MA - vinanet.vn
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Ge - The National Law Review
Phathom Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | PHAT | US71722W1071 - marketscreener.com
PHAT Holds Near $9.18 as Phathom Pharmaceuticals Consolidates Within Key Trading RangeStop Hunt - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect - ACCESS Newswire
Why (PHAT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Edges Higher at $8.57: Support Holds as Resistance LoomsTriangle Correction - dars.gov.et
Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuti - The National Law Review
Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Reach Out - ACCESS Newswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5%Here's Why - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Jan 13 '26 |
Option Exercise |
10.30 |
8,750 |
90,125 |
131,000 |
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
1.01%
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):